Progressive external ophthalmoplegia
https://doi.org/10.30629/2658-7947-2019-24-6-4-13
Abstract
Progressive external ophthalmoplegia (PEO) is characterized by progressive bilateral ptosis and eye movement disturbances in horizontal and vertical directions and represents a typical symptom of many mitochondrial disorders, but not a separate disease. PEO often occurs together with other systemic manifestations of mitochondrial disfunction. Correct and early diagnosis of PEO is essential for optimal management of these patients. In this review we collected the last data about etiology, spectrum of clinical symptoms, differential diagnosis, diagnostical methods and treatment options for isolated chronic PEO and other PEO-associated mitochondrial syndromes.
About the Authors
E. V. Iakovenko
Research Center of Neurology
Russian Federation
Russian Federation
Moscow.
E. Yu. Fedotova
Research Center of Neurology
Russian Federation
Russian Federation
Fedotova Ekaterina Yu. — Head of the Department of Neurogenetics in Research Center of Neurology.
Moscow.
S. N. Illarioshkin
Research Center of Neurology
Russian Federation
Russian Federation
Moscow.
References
1. Von Graefe A. Symptomen lehreder Augenmuskellahmungen. Berlin: Peters, 1867.
2. Kearns T.P., Sayre G.P. Retinitis pigmentosa, external ophthalmophegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol. 1958;60(2):280-9.
3. Drachman D.A. Ophthalmoplegia plus. The neurodegenerative disorders associated with progressive external ophthalmoplegia. Arch Neurol. 1968;18(6):654-74.
4. Reske-Nielsen E., Lou H.C., Lowes M. Progressive external ophthalmoplegia. Evidence for a generalised mitochondrial disease with a defect in pyruvate metabolism. Acta Ophthalmol (Copenh). 1976;54(5):553-73.
5. Olson W., Engel W.K., Walsh G.O., Einaugler R. Oculocraniosomatic neuromuscular disease with ragged-redfibers. Arch Neurol. 1972;26(3):193-211.
6. Elliott H.R., Samuels D.C., Eden J.A., Relton C.L., Chinnery P.F. Pathogenicmitochondrial DNA mutations are common in the general population. Am J HumGenet.2008;83(2):254-60.
7. Schaefer A.M., McFarland R., Blakely E.L., et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol. 2008;63:35-9.
8. Petty R.K., Harding A.E., Morgan-Hughes J.A. The clinical features of mitochondrial myopathy. Brain. 1986;109(5):915-38.
9. Bucelli R.C., Lee M.S., McClelland C.M. Chronic Progressive External Ophthalmoplegia in the Absence of Ptosis. J Neuroophthalmol. 2016 Sep;36(3):27-4.
10. Shorr N., Christenbury J.D., Goldberg R.A. Management of ptosis in chronic progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg. 1987;3(3):141-5.
11. Hart P.E., De Vivo D.C., Schapira A.H. Clinical features of the mitochondrial encephalomyopathies. In: Shapira A.H., DiMauro S., eds. Mitochondrial Disorders in Neurology 2. Woburn: Butterworth-Heineman; 2002:35-68.
12. Yu Wai Man C.Y., Smith T., Chinnery P.F., Turnbull D.M., Griffiths P. G. Assessment of visual function in chronic progressive external ophthalmoplegia. Eye (Lond). 2006;20(5):564-8.
13. Pfeffer G., Sirrs S., Wade N.K., Mezei M.M. Multisystem disorder in late-onset chronic progressive external ophthalmoplegia. Can J Neurol Sci. 2011;38(1):119-23.
14. Phadke M., Lokeshwar M.R., Bhutada S., Tampi C., Saxena R., Kohli S., Shah K.N. KearnsSayre Syndrome — case report with review of literature. Indian JPediatr. 2012 May;79(5):650-4.
15. Reichmann H., Degoul F., Gold R., Meurers B., Ketelsen U.P., Hartmann J., Marsac C., Lestienne P. Histological, enzymatic and mitochondrial DNA studies in patients with Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia. Eur Neurol. 1991;31(2):108-13.
16. Tsang S.H., Aycinena A.R.P., Sharma T. Mitochondrial Disorder: Kearns-Sayre Syndrome. Adv. Exp. Med. Biol. 2018;1085:161-162.
17. Saldana-Martinez A., Munoz M.L., Perez-Ramirez G., Montiel-Sosa J.F., Montoya J., Emperador S., et al. Whole sequence of the mitochondrial DNA genome of Kearns Sayre Syndrome patients: Identification of deletions and variants. Gene. 2019 Mar 10;688:171-181.
18. Miller N.R., Walsh F.B., Hoyt W.F. Walsh and Hoyt’s clinical neuroophthalmology. Vol. 1. 6th ed. Philadelphia, Pa; London: Lippincott Williams & Wilkins; 2005.
19. Mullie M.A., Harding A.E., Petty R.K., Ikeda H., Morgan-Hughes J.A., Sanders M.D. The retinal manifestations of mitochondrial myopathy. A study of 22 cases. Arch Ophthalmol. 1985;103(12):1825-30.
20. Young T.J., Shah A.K., Lee M.H., Hayes D.L. Kearns-Sayre syndrome: a case report and review of cardiovascular complications. Pacing Clin Electrophysiol. 2005;28(5):454-7.
21. Chu B.C., Terae S., Takahashi C., Kikuchi Y, Miyasaka K., Abe S. et al. MRI of the brain in the Kearns-Sayre syndrome: report of four cases and a review. Neuroradiology. 1999;41(10):759-64.
22. Hanisch F., Kornhuber M., Alston C.L., Taylor R.W., Deschauer M., Zierz S. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. J Neurol Neurosurg Psychiatry. 2015;86(6):630-4.
23. El-Hattab A.W., Adesina A.M., Jones J., Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol GenetMetab. 2015;116(1-2):4-12.
24. Hirano M., Pavlakis S.G. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neurol. 1994;9(1):4-13.
25. Yu-Wai-Man P., Griffiths P.G., Gorman G.S., et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133(Pt 3):771-86.
26. Liskova P., Ulmanova O., Tesina P., et al. Novel OPA1 missense mutation in a family with optic atrophy and severe widespread neurological disorder. Acta Ophthalmol. 2013;91(3):225-31.
27. Amati-Bonneau P., Valentino M.L., Reynier P. et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain. 2008;131(Pt 2):338-51.
28. Lee A.G., Brazis P.W. Chronic progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2002;2(5):413-7.
29. Liu G.T., Volpe N.J., Galetta S.L. Neuro-Ophthalmology: Diagnosis and Management. 2nd ed. Philadelphia, PA: Elsevier (2010).
30. Okamoto K., Ito J., Tokiguchi S., Furusawa T. Atrophy of bilateral extraocular muscles — CT and clinical features of seven patients. J Neuro-Ophthalmol. 1996;16(4):286-8.
31. Ortube M.C., Bhola R., Demer J.L. Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: specific diagnostic findings. J Aapos. 2006;10(5):414-8.
32. Mitochondrial Medicine Society’s Committee on Haas R.H., Parikh S. et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008;94(1):16-37.
33. Pfeffer G., Chinnery P.F. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45(1):4-16.
34. Milone M., Wong L.J. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110(1-2):35-41.
35. Krendel D.A., Sanders D.B., Massey J.M. Single fiber electromyography in chronic progressive external ophthalmoplegia. Muscle Nerve. 1987;10(4):299-302.
36. Trivedi M., Goldstein A., Arora G. Prophylactic pacemaker placement at first signs of conduction disease in Kearns-Sayre syndrome. Cardiol Young. 2018 Dec;28(12):1487-1488.
37. Shemesh A., Margolin E. Kearns Sayre Syndrome. 2019 Jun 3. StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan.
38. Nguyen M.T.B., Micieli J., Margolin E. Teaching NeuroImages: Kearns-Sayre syndrome. Neurology. 2019 Jan 29;92(5):e519-e520.
39. Berio A., Piazzi A., Traverso C.E. Kearns-Sayre syndrome with facial and white matter extensive involvement: a (mitochondrial and nuclear gene related?) neurocristopathy? Pediatr Med Chir. 2017 Dec 15;39(4):169.
40. Moraes C.T., DiMauro S., Zeviani M., et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989;320(20):1293-9.
41. Lopez-Gallardo E., Lopez-Perez M.J., Montoya J., Ruiz-Pesini E. CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion. 2009;9(5):314-7.
42. Mancuso M., Orsucci D., Angelini C., et al. Redefining phenotypes associated with mitochondrial DNA single deletion. J Neurol. 2015;262(5):1301-9.
43. Schon E.A., Rizzuto R., Moraes C.T. et al. (1989). A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science. 244:346-349.
44. Lamantea E., Tiranti V, Bordoni A. et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002;52(2):211-9.
45. Kaukonen J., Juselius J.K., Tiranti V et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000;289(5480):782-5.
46. Spelbrink J.N., Li F.Y., Tiranti V., et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet. 2001;28(3):223-31.
47. Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., Suomalainen A. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet. 2009;85(2):290-5.
48. Ronchi D., Di Fonzo A., Lin W., et al. Mutations in DNA2 link progressive myopathy to mitochondrial DNA instability. Am J Hum Genet. 2013;92(2):293-300.
49. Hudson G., Amati-Bonneau P., Blakely E.L., et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain. 2008;131(Pt 2):329-37.
50. Hirano M., DiMauro S. ANT1, twinkle, POLG, and TP — new genes open our eyes to ophthalmoplegia. Neurology. 2001;57(12):2163-5.
51. Gonzalez-Vioque E., Blazquez A., Fernandez-Moreira D., et al. Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population. Arch Neurol. 2006;63(1):107-11.
52. HorgaA., Pitceathly R.D., Blake J.C., et al. Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia. Brain. 2014;137(Pt 12):3200-12.
53. Pfeffer G., Gorman G.S., Griffin H., et al. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain. 2014 May;137(Pt 5):1323-36.
54. Lamantea E., Tiranti V., Bordoni A., et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002;52(2):211-9.
55. Nishino I., Spinazzola A., Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999;283(5402):689-92.
56. Kornblum C., Nicholls T.J., Haack T.B., et al. Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet. 2013;45(2):214-9.
57. Reyes A., Melchionda L., Nasca A., et al. RNASEH1 mutations impair mtDNA replication and cause adult-onset mitochondrial encephalomyopathy. Am J Hum Genet. 2015;97(1):186-93.
58. McClelland C., Manousakis G., Lee M.S. Progressive External Ophthalmoplegia. CurrNeurolNeurosciRep. 2016 Jun;16(6):53.
59. Sundaram C., Meena A.K., Uppin M.S., et al. Contribution of muscle biopsy and genetics to the diagnosis of chronic progressive external opthalmoplegia of mitochondrial origin. J Clin Neurosci. 2011;18(4):535-8.
60. Schaefer A.M., Blakely E.L., Griffiths P.G., Turnbull D.M., Tay¬lor R.W. Ophthalmoplegia due to mitochondrial DNA disease: the need for genetic diagnosis. Muscle Nerve. 2005;32(1):104-7.
61. Pfeffer G., Waters P. J., Maguire J., Vallance H.D., Wong V A., Mezei M.M. Levator palpebrae biopsy and diagnosis of progressive external ophthalmoplegia. Can J Neurol Sci. 2012;39(4):520-4.
62. Wong L.J. Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion. 2013;13(4):379-87.
63. Gonzalez-Moron D., Bueri J., Kauffman M.A. Progressive ex¬ternal ophthalmoplegia (PEO) due to a mutation in the C10orf2 (PEO1) gene mimicking a myasthenic crisis. BMJ Case Rep. 2013;2013.
64. Behbehani R., Sharfuddin K., Anim J.T. Mitochondrial ophthal-moplegia with fatigable weakness and elevated acetylcholine re-ceptor antibody. JNeuroophthalmol. 2007;27(1):41-4.
65. Wong K.T., Dick D., Anderson J.R. Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Neuromuscul Disord. 1996; 6(3):163-6.
66. Yum K., Wang E.T., Kalsotra A. Myotonic dystrophy: disease re¬peat range, penetrance, age of onset, and relationship between re¬peat size and phenotypes. Curr Opin Genet Dev. 2017; 44:30-7.
67. Poulton J., Harley H.G., Dasmahapatra J., Brown G.K., Pot¬ter C.G., Sykes B. Mitochondrial DNA does not appear to influence the congenital onset type of myotonic dystrophy. J Med Genet. 1995;32(9):732-5.
68. Hamedani A.G., Gold D.R. Eyelid Dysfunction in Neurodegen-erative, Neurogenetic,and Neurometabolic Disease. Front Neu¬rol. 2017; Jul 18;8:329.
69. Kiferle L., Orsucci D., Mancuso M., Lo Gerfo A., Petrozzi L., Siciliano G., et al. Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: a case report and an update on the state of the art. Neurosci Lett. 2013; 556:1-4.
70. Amboni M., Pellecchia M.T., Cozzolino A., Picillo M., Vitale C., Barone P., et al. Cerebellar and pyramidal dysfunctions, palpe¬bral ptosis and weakness as the presenting symptoms of PARK-2. Mov Disord. 2009;24(2):303-5.
71. Zuhlke C., Mikat B., Timmann D., Wieczorek D., Gillessen-Kaesbach G., Burk K. Spinocerebellar ataxia 28: novel AFG3L2 mutation in a German family with young onset, slow progression and saccadic slowing. Cerebellum Ataxias. 2015;2:19.
72. Gorman G.S., Pfeffer G., Griffin H., Blakely E.L., Kurzawa-Akanbi M., Gabriel J., et al. Clonal expansion of secondary mito¬chondrial DNA deletions associated with spinocerebellar ataxia type 28. JAMA Neurol. 2015;72(1):106-11.
73. Kersten R.C., de Conciliis C., Kulwin D.R. Acquired ptosis in the young and middle-aged adult population. Ophthalmology. 1995;102:924-8.
74. Verhulst S., Smet H., De Wilde F., Tassignon M.J. Levator apo-neurosis dehiscence in a patient treated with botulinum toxin for blepharospasms and eyelid apraxia. Bull Soc Belge Ophthalmol. 1994;252:51-3.
75. Ng J., Papandreou A., Jeales S.J., Kurian M.A. Monoamine neurotransmitter disorders — clinical advances and future direc-tions. Nat Rev Neurol. 2015;11:567-84.
76. Pineles S.L., Demer J.L., Holland G.N., Ransome S.S., Bonelli L., Velez F.G. External ophthalmoplegia in human immunode¬ficiency virus-infected patients receiving antiretroviral therapy. Jaapos. 2012;16(6):529-33.
77. Pfeffer G., Cote H.C., Montaner J.S., Li C.C., Jitratkosol M., Mezei M.M. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HlV therapy. Neurology. 2009;73(1):71-2.
78. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin thera¬py induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94-102.
79. Fraunfelder F.W., Richards A.B. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reduc¬tase inhibitor use. Ophthalmology. 2008;115(12):2282-5.
80. Lapid O., Lapid-Gortzak R., Barr J., Rosenberg L. Eyelid crutches for ptosis: a forgotten solution. Plast Reconstr Surg. 2000;106(5):1213-4.
81. de Castro F.A., Cruz A.A., Sobreira C.F. Brow motil¬ity in mitochondrial myopathy. Ophthal Plast Reconstr Surg. 2010;26(6):416-9.
82. Wallace D.K., Sprunger D.T., Helveston E.M., Ellis F.D. Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Ophthalmology. 1997;104(4):695-700.
83. Finsterer J., Haberler C., Schmiedel J. Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol. 2005;28:148-9.
84. Parikh S., Goldstein A., Koenig M.K., Scaglia F., Enns G.M., Saneto R. et al. Diagnosis and management of mitochondrial dis¬ease: a consensus statement from the Mitochondrial Medicine Society. Genet Med: Off J Am Coll Med Genet. 2015;17:689-701.
85. Muraresku C.C., McCormick E.M., Falk M.J. Mitochondrial Disease: Advances in clinical diagnosis, management, therapeu¬tic development, and preventative strategies. Curr Genet Med Rep. 2018 Jun;6(2):62-72.
86. Sadun A.A., Chicani C.F., Ross-Cisneros F.N., Barboni P., Thoolen M., Shrader W.D. et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neu¬ropathy. Arch Neurol. 2012 Mar;69(3):331-8.
Review
For citations:
Iakovenko E.V., Fedotova E.Yu., Illarioshkin S.N. Progressive external ophthalmoplegia. Russian neurological journal. 2019;24(6):4-13. (In Russ.) https://doi.org/10.30629/2658-7947-2019-24-6-4-13
Views:
2751
Email this article 